Manufacturing of NK cells for the clinic: the Spanish experience

Dr. Antonio Perez-Martinez, MD, PhD, is a Medical Specialist in Pediatrics and the Head of Pediatric Hematology and Oncology Service at the University Hospital La Paz, Madrid, Spain. He is also the Head of the Pediatric Department at the Autonomous University of Madrid, Spain, and the Principle Investigator at the Foundation for Biomedical Research, Hospital La Paz, and has experience as the Principal Investigator of over 20 active research projects.

Dr. Giedlin iscurrently the VP, Head of Tech Ops at Senti BioSciences supporting theallogeneic NK-CAR programs. Before his joining Senti, he led the PD groups atPACT Pharma (non-viral process for generating autologous neoTcR+ T cells),Poseida (non-viral process for generating autologous CAR-T’s), and Novartis(clinical and commercial manufacturing process for Kymriahâ). His experience covers over 25 years of variousapproaches to harness the immune response to treat cancer and infectiousdisease, starting with Proleukinâ rIL-2 (aldesleukin; Chiron), Oncolytic adenovirus(Onyx), Listeria-based cancer vaccines (Cerus), and CCR5 knockout CD4+ T cellsfor HIV+ patients (Sangamo).  Inaddition, he led the implementation of AAV clinical manufacturing to supportthe Hemophilia, LSD, and neurodegenerative disease programs.

A Passionate scientist about cancer research and immunology. 10 years of extensive experience in cutting-edge and novel cell therapy technologies such as CRISPR-based Gene-editing, CAR T-cells, CAR-NK cells, and several other GMP protocols, including expansion and cryopreservation of feeder cells. Proficient in a wide range of highly specialized aseptic cell manipulation techniques, cell culture, and development of new procedures.